Search
Volixibat
go.drugbank.com/drugs/DB13914InvestigationalIf approved for use, it will be the first available agent for the treatment of NASH. … According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments
PYM50018
go.drugbank.com/drugs/DB05126ExperimentalIt is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).
Ceramide NP
go.drugbank.com/drugs/DB14111InvestigationalIt is widely used as a moisturizer in various cosmetic and personal products. Together with ceramide 1, they synergistically improve the skin barrier function in humans [A27232, A27233].
Synonyms: Cer(t18:0/18:1n-9)Triazavirin
go.drugbank.com/drugs/DB15622Investigational[A191709,A191625,A191916] It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications.
SYNB1020
go.drugbank.com/drugs/DB17667InvestigationalIt was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer
Mivebresib
go.drugbank.com/drugs/DB21300InvestigationalThe usage of the INN stem '-bresib' in the name indicates that Mivebresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic.
Ramoplanin
go.drugbank.com/drugs/DB04952ExperimentalRamoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
Davamotecan pegadexamer
go.drugbank.com/drugs/DB05899InvestigationalEP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound camptothecin.
Fluasterone
go.drugbank.com/drugs/DB06250ExperimentalHas antiproliferative effects on HIV-1 and reduces HIV-1 replication.
beta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1 dia...